PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Müller, T.D. ; Finan, B.* ; Bloom, S.R.* ; D'Alessio, D.* ; Drucker, D.J.* ; Flatt, P.R.* ; Fritsche, A. ; Gribble, F.* ; Grill, H.J.* ; Habener, J.F.* ; Holst, J.J.* ; Langhans, W.* ; Meier, J.J.* ; Nauck, M.A.* ; Perez-Tilve, D.* ; Pocai, A.* ; Reimann, F.* ; Sandoval, D.A.* ; Schwartz, T.W.* ; Seeley, R.J.* ; Stemmer, K. ; Tang-Christensen, M.* ; Woods, S.C.* ; DiMarchi, R.D.* ; Tschöp, M.H.

Glucagon-like peptide 1 (GLP-1).

Mol. Metab. 30, 72-130 (2019)
Verlagsversion DOI
Open Access Gold
Creative Commons Lizenzvertrag
Background: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, and modulation of rodent β-cell proliferation. GLP-1 also has cardio- and neuroprotective effects, decreases inflammation and apoptosis, and has implications for learning and memory, reward behavior, and palatability. Biochemically modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clinical use for the treatment of type-2 diabetes, and several GLP-1-based pharmacotherapies are in clinical evaluation for the treatment of obesity. Scope of review: In this review, we provide a detailed overview on the multifaceted nature of GLP-1 and its pharmacology and discuss its therapeutic implications on various diseases. Major conclusions: Since its discovery, GLP-1 has emerged as a pleiotropic hormone with a myriad of metabolic functions that go well beyond its classical identification as an incretin hormone. The numerous beneficial effects of GLP-1 render this hormone an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, and neurodegenerative disorders
Impact Factor
Scopus SNIP
Scopus
Cited By
Altmetric
6.181
1.435
527
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Diabetes ; Glp-1 ; Glucagon ; Incretin ; Insulin ; Obesity
Sprache englisch
Veröffentlichungsjahr 2019
HGF-Berichtsjahr 2019
ISSN (print) / ISBN 2212-8778
e-ISSN 2212-8778
Zeitschrift Molecular Metabolism
Quellenangaben Band: 30, Heft: , Seiten: 72-130 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort Amsterdam
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)
Institute of Diabetes Research and Metabolic Diseases (IDM)
POF Topic(s) 30201 - Metabolic Health
90000 - German Center for Diabetes Research
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-502200-001
G-501900-221
G-502400-001
DOI 10.1016/j.molmet.2019.09.010
Scopus ID 85073166351
Erfassungsdatum 2019-10-21
[➜Korrektur melden]